Structure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Update

Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) was the target of a large growth in short interest in January. As of January 15th, there was short interest totalling 10,750,000 shares, a growth of 5.8% from the December 31st total of 10,160,000 shares. Based on an average daily trading volume, of 824,600 shares, the short-interest ratio is presently 13.0 days. Currently, 19.8% of the company's stock are sold short.

Institutional Investors Weigh In On Structure Therapeutics

Several large investors have recently made changes to their positions in GPCR. GAMMA Investing LLC raised its position in Structure Therapeutics by 4,155.6% in the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock worth $31,000 after acquiring an additional 1,122 shares during the period. FNY Investment Advisers LLC bought a new stake in shares of Structure Therapeutics in the 4th quarter worth approximately $40,000. Assetmark Inc. lifted its stake in Structure Therapeutics by 120.0% in the third quarter. Assetmark Inc. now owns 1,318 shares of the company's stock valued at $58,000 after purchasing an additional 719 shares during the last quarter. Jones Financial Companies Lllp grew its holdings in Structure Therapeutics by 29.8% during the fourth quarter. Jones Financial Companies Lllp now owns 4,228 shares of the company's stock valued at $115,000 after purchasing an additional 971 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in Structure Therapeutics by 60.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company's stock worth $158,000 after buying an additional 1,420 shares during the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Trading Down 2.2 %

Shares of GPCR stock traded down $0.68 during trading on Thursday, hitting $30.02. The company's stock had a trading volume of 969,565 shares, compared to its average volume of 793,619. The business has a fifty day moving average of $29.40 and a 200-day moving average of $35.03. The company has a market cap of $1.72 billion, a PE ratio of -40.57 and a beta of -2.76. Structure Therapeutics has a 52 week low of $23.50 and a 52 week high of $62.74.

Analysts Set New Price Targets

GPCR has been the subject of a number of research reports. HC Wainwright reissued a "buy" rating and issued a $80.00 price objective on shares of Structure Therapeutics in a research note on Thursday, December 19th. JMP Securities restated a "market outperform" rating and set a $91.00 price target on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Finally, Stifel Nicolaus assumed coverage on shares of Structure Therapeutics in a report on Wednesday, January 8th. They set a "buy" rating and a $50.00 price objective for the company. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $81.29.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.